research feed

Every NR4A2 paper, in plain English

PubMed and the Europe PMC preprint servers are queried daily for NR4A2 and NURR1, back to the earliest records. Each abstract is summarised locally by Qwen3.6 35B and tagged by relevance to a parent of an NR4A2 child. Source links go straight to the paper.

subscribe (Atom feed) · high and medium relevance only

registered clinical trials

Every ClinicalTrials.gov study whose record mentions NR4A2 or NURR1. Most use NURR1 as a Parkinson's biomarker rather than testing anything for this syndrome, so read the conditions line. Studies still open come first. Last checked 2026-09-14.

completed or inactive (4) ›
medium2009-12-11 · BMC neuroscience

Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.

Friling S, Bergsland M, Kjellander S

Activating the Retinoid X Receptor (RXR) protects dopamine neurons from degeneration in laboratory models of Parkinson's disease. This suggests RXR is a promising target for therapies that could preserve these brain cells.

  • RXR ligands protect dopamine neurons from toxin-induced damage in rat and stem cell cultures.
  • The protective effect is selective for dopamine neurons and does not work against all stress types.
  • Stem cell-derived dopamine cultures provide a reliable platform for testing potential treatments.
  • This study uses animal and cell models, not human patients.
medium2009-12-04 · Cell stem cell

Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway.

Chung S, Leung A, Han BS, Chang MY, Moon JI, Kim CH, Hong S, Pruszak J, Isacson O, Kim KS

Researchers identify a specific genetic loop involving Wnt1 and Lmx1a that works with other signals to guide stem cells into becoming midbrain dopamine neurons. This process directly regulates Nurr1 (NR4A2) and Pitx3, which are critical for the development of these specific brain cells. The study demonstrates that activating multiple pathways together significantly improves the production of these neurons in laboratory settings.

  • Wnt1 and Lmx1a form a loop that regulates Nurr1 (NR4A2) during neuron development.
  • This loop works synergistically with the SHH-FoxA2 pathway to boost dopamine neuron creation.
  • The findings come from stem cell models and embryonic mice, not human patients.
  • Nurr1 and Pitx3 are direct targets of this regulatory mechanism in midbrain development.
medium2009-11-11 · Progress in neuro-psychopharmacology & biological psychiatry

Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.

Gibrat C, Bousquet M, Saint-Pierre M, Lévesque D, Calon F, Rouillard C, Cicchetti F

Cystamine protects dopamine-producing neurons in mice by increasing brain-derived neurotrophic factor (BDNF) levels. This study provides preclinical evidence that cystamine may preserve Nurr1 expression and prevent neuronal loss in a Parkinson's disease model.

  • Cystamine increases BDNF mRNA in the substantia nigra of mice.
  • Low-dose cystamine protects against MPTP-induced dopamine neuron loss.
  • Higher doses show no benefit or cause non-specific effects.
  • Protection correlates with preserved Nurr1 mRNA expression.
  • Results suggest BDNF up-regulation as the key mechanism.
medium2009-09-24 · Journal of neurochemistry

Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons.

Hwang DY, Hong S, Jeong JW, Choi S, Kim H, Kim J, Kim KS

The transcription factor Pitx3 directly activates the genes for dopamine transporters in midbrain neurons, working alongside Nurr1 to regulate dopamine function. This study identifies a specific molecular mechanism by which these two proteins coordinate to maintain healthy dopamine signaling pathways.

  • Pitx3 directly activates vesicular monoamine transporter 2 and dopamine transporter genes.
  • Loss of Pitx3 significantly reduces the expression of key dopamine transporters.
  • Pitx3 and Nurr1 likely coordinate to regulate dopamine neuron survival and function.
  • This mechanism is observed in mouse models of midbrain dopamine neurons.
medium2009-09-01 · Stem cells (Dayton, Ohio)

Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.

Jo AY, Kim MY, Lee HS, Rhee YH, Lee JE, Baek KH, Park CH, Koh HC, Shin I, Lee YS, Lee SH

Engineered Nurr1 proteins that resist cellular degradation significantly improve the survival and stability of dopamine neurons in laboratory settings. This modification prevents the loss of therapeutic potential often seen when these cells are transplanted, suggesting a viable strategy for future cell-based treatments.

  • Nurr1 protein naturally degrades via Akt-mediated phosphorylation during neuron development.
  • A mutant Nurr1 resists this degradation and maintains high protein levels longer.
  • Neurons with stable Nurr1 show enhanced survival and sustained dopamine phenotypes.
  • The approach improves cell viability in both lab cultures and animal models.
medium2009-06-03 · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Dopamine genes and nicotine dependence in treatment-seeking and community smokers.

Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, Tyndale RF, Benowitz NL, Lerman C, Swan GE

This study identifies a genetic interaction between NR4A2 and SLC6A3 that influences nicotine dependence severity in smokers. The findings confirm that the NR4A2 protein regulates the transcription of the dopamine transporter gene, providing mechanistic insight into dopaminergic pathways.

  • NR4A2 variants interact with SLC6A3 to affect nicotine dependence levels.
  • The study confirms NURR1 regulates dopamine transporter gene transcription.
  • Each significant SNP accounts for approximately 1% of variance in dependence scores.
  • Results are based on human genetic data from smokers, not clinical trials.
medium2009-04-03 · Cell

A Nurr1 pathway for neuroprotection.

Bensinger SJ, Tontonoz P

Nurr1 protects dopaminergic neurons by suppressing inflammatory gene expression in astrocytes and microglia. This mechanism suggests that reducing neuroinflammation could be a therapeutic strategy for conditions involving Nurr1 dysfunction.

  • Nurr1 suppresses inflammation in brain support cells to protect dopamine neurons.
  • This pathway offers a potential target for treating neurodegenerative symptoms.
  • The study uses mouse models to demonstrate this protective mechanism.
medium2009-04-03 · Cell

A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death.

Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK

Nurr1 protects dopaminergic neurons from inflammation-induced death by suppressing pro-inflammatory mediators in microglia and astrocytes. Reduced Nurr1 levels lead to exaggerated inflammatory responses that cause neuronal loss, providing a mechanistic link between Nurr1 mutations and neurodegeneration.

  • Nurr1 inhibits pro-inflammatory mediators in microglia and astrocytes.
  • Reduced Nurr1 causes exaggerated inflammation leading to dopaminergic neuron death.
  • Nurr1 recruits CoREST to repress inflammatory gene transcription via NF-kappaB-p65.
  • This mechanism explains how Nurr1 mutations contribute to Parkinson's disease pathology.
medium2009-04-01 · Journal of bioscience and bioengineering

Differentiation of dopaminergic neurons from human embryonic stem cells: modulation of differentiation by FGF-20.

Shimada H, Yoshimura N, Tsuji A, Kunisada T

This study demonstrates that adding FGF-20 and FGF-2 to human embryonic stem cell cultures improves the generation of midbrain dopaminergic neurons. The treatment increases key transcription factors like NURR1, which is the protein affected by NR4A2 mutations, suggesting a potential pathway for future cell-based therapies.

  • FGF-20 and FGF-2 enhance differentiation of human stem cells into dopaminergic neurons.
  • Treatment boosts expression of NURR1, PITX3, LMX1B, and EN1 transcription factors.
  • The method works without support cells, offering a cleaner protocol for neuron production.
  • Results aim to improve cell transplantation strategies for Parkinson's disease.
lower-relevance papers (31) ›
low2009-12-08 · Cell research

The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives.

Wan F, Lenardo MJ

This review describes how the transcription factor NF-kappaB is regulated inside the cell nucleus, identifying various proteins that influence its activity. It mentions Nurr1 (NR4A2) as one of many nuclear regulators of NF-kappaB but does not focus on NR4A2 biology or function. The paper provides general background on immune and cellular signaling rather than specific insights into NR4A2-related syndromes.

  • NF-kappaB regulates cell growth, death, and immune responses through nuclear signaling.
  • Nurr1 is listed as a nuclear regulator of NF-kappaB transcriptional activity.
  • The paper reviews general mechanisms of NF-kappaB regulation in the nucleus.
  • No specific findings regarding NR4A2 mutations or related neurological conditions are presented.
low2009-12-05 · The Journal of steroid biochemistry and molecular biology

Cell density is a critical determinant of aromatase expression in adipose stromal cells.

Ghosh S, Hu Y, Li R

High cell density in fat tissue increases aromatase activity, which boosts estrogen production. This process involves the downregulation of NR4A family genes, including Nurr1 (NR4A2), suggesting that local tissue environment influences gene expression.

  • High cell density stimulates aromatase gene expression in adipose stromal cells.
  • Increased cell number reduces NR4A family member expression, including Nurr1.
  • Knocking down Nurr1 further increases aromatase expression in these cells.
  • The study focuses on breast cancer risk and estrogen biosynthesis in fat tissue.
low2009-11-20 · Neurotoxicity research

Ontogenetic expression of dopamine-related transcription factors and tyrosine hydroxylase in prenatally stressed rats.

Katunar MR, Saez T, Brusco A, Antonelli MC

Prenatal stress in rats permanently alters the expression of dopamine-related transcription factors, including Nurr1 (NR4A2), specifically in brain regions controlling motivation and emotion. These molecular changes suggest that early-life insults can disrupt dopamine pathways long-term, potentially leading to behavioral impairments in adulthood.

  • Prenatal stress increases Nurr1 expression permanently in the rat ventral tegmental area.
  • Stress decreases Pitx3 expression at postnatal day 28 but restores it by day 60.
  • Tyrosine hydroxylase levels drop early but return to normal before puberty.
  • Changes target the mesolimbic pathway, affecting reward and emotional behavior.
  • The study links prenatal stress to long-term dopamine system dysregulation.
low2009-11-17 · Neuroimmunomodulation

Involvement of nuclear factor-kB and Nurr-1 in cytokine-induced transcription of proopiomelanocortin gene in AtT20 corticotroph cells.

Takayasu S, Iwasaki Y, Nigawara T, Asai M, Yoshida M, Kageyama K, Suda T

This study shows that inflammatory signals increase Nurr-1 levels in mouse pituitary cells to boost stress hormone production. It identifies a molecular pathway where immune factors directly regulate the NR4A2 gene in non-neuronal tissue. This mechanism is unrelated to the dopaminergic neuron loss seen in NR4A2-related movement disorders.

  • Study uses mouse pituitary tumor cells, not human patients or brain tissue.
  • Focuses on immune-stress hormone pathways, not dopamine or motor function.
  • No potential treatments for NR4A2 syndrome are identified or tested.
low2009-11-11 · The Journal of neuroscience : the official journal of the Society for Neuroscience

Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development.

Quina LA, Wang S, Ng L, Turner EE

This study maps a specific genetic pathway in mice that controls the development of the habenula, a brain structure involved in mood and reward processing. It identifies Nurr1 (NR4A2) as a key component downstream of another transcription factor, Brn3a, which regulates genes necessary for proper neural connectivity.

  • Nurr1 acts downstream of Brn3a to regulate habenula development in mice.
  • The study defines a specific gene regulatory pathway for this brain region.
  • Brn3a mutants show failed innervation despite correct tract direction.
  • Research focuses on embryonic mouse models, not human patients or treatments.
low2009-11-10 · Journal of neuroscience methods

Differentiation of mouse Neuro 2A cells into dopamine neurons.

Tremblay RG, Sikorska M, Sandhu JK, Lanthier P, Ribecco-Lutkiewicz M, Bani-Yaghoub M

This study establishes a method to generate dopamine-producing neurons from mouse cell lines using dibutyryl cyclic AMP. It identifies specific molecular pathways that enhance dopamine production in these cells but does not involve human patients or clinical treatments.

  • Mouse N2a cells differentiate into dopamine neurons when treated with dibutyryl cyclic AMP.
  • Other common factors like GDNF and retinoic acid do not increase dopamine production in this model.
  • The process relies on CREB signaling pathways within the mouse cell line.
  • This is a preclinical tool for laboratory assays, not a human therapy.
low2009-10-25 · Biochemical and biophysical research communications

NR4A orphan nuclear receptors influence retinoic acid and docosahexaenoic acid signaling via up-regulation of fatty acid binding protein 5.

Volakakis N, Joodmardi E, Perlmann T

This study identifies fatty acid binding protein 5 (FABP5) as a direct target of NR4A receptors in human kidney cells. It demonstrates that NR4A proteins increase FABP5 levels, which in turn enhances signaling pathways for retinoic acid and docosahexaenoic acid.

  • NR4A receptors directly bind to and up-regulate the FABP5 gene in HEK293 cells.
  • Increased FABP5 enhances retinoic acid signaling through PPARbeta/delta pathways.
  • FABP5 mediates the activation of RXR by docosahexaenoic acid (DHA).
  • Other NR4A family members also up-regulate FABP5 expression similarly to Nurr1.
low2009-10-13 · Gene expression patterns : GEP

Organization of the human embryonic ventral mesencephalon.

Nelander J, Hebsgaard JB, Parmar M

This study maps the genetic development of dopamine-producing neurons in the human embryonic brain and confirms that these developmental processes closely mirror those found in mice. It identifies specific genes, including NURR1, that are active during the formation of these critical neural structures.

  • NURR1 is expressed in developing human dopamine neurons alongside other key markers like TH and PITX3.
  • Human embryonic brain development follows a pattern similar to mouse models for ventral mesencephalon organization.
  • The study confirms the spatial and temporal expression of developmental regulators in human tissue.
low2009-10-10 · Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Neuroinflammation in Parkinson's disease.

Lee JK, Tran T, Tansey MG

This review summarizes how inflammation and oxidative stress contribute to the loss of dopamine-producing neurons in Parkinson's disease. It highlights interactions between immune cells and specific genes, including Nurr1, in driving neurodegeneration.

  • Inflammation drives oxidative stress and neuron death in Parkinson's disease pathways.
  • Microglia activation is linked to both pre-clinical models and human clinical studies.
  • Systemic inflammation can trigger harmful immune responses in the brain.
  • Nurr1 interacts with other proteins to promote neurodegeneration alongside inflammation.
  • Anti-inflammatory drugs may lower Parkinson's risk based on epidemiological data.
low2009-09-16 · Brain research

Expression pattern of NuIP gene in adult mouse brain.

Luo Y, Sarabi SA, Backman C, Shan L, Hoffer B, Federoff H

This study maps where the NuIP protein is located in adult mouse brains and finds it overlaps with Nurr1 in key motor and cognitive areas. It shows NuIP is present in midbrain dopaminergic neurons but does not test any treatments or human outcomes.

  • NuIP co-exists with Nurr1 in the substantia nigra and ventral tegmental area of adult mice.
  • NuIP appears in striatum, hippocampus, and cortex, suggesting roles in motor control and memory.
  • The research uses mouse brain tissue and does not involve human patients or clinical trials.
low2009-09-03 · Molecular immunology

Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis.

Aherne CM, McMorrow J, Kane D, FitzGerald O, Mix KS, Murphy EP

This study shows that NR4A2 drives inflammation in arthritis by increasing levels of IL-8, a chemical that attracts immune cells to joints. Treatment with methotrexate reduces both NR4A2 and IL-8 levels in patients, linking the gene to inflammatory activity rather than neurological function.

  • NR4A2 increases IL-8 production in human joint cells when activated by inflammation signals.
  • NR4A2 works with NF-kappaB to boost IL-8 transcription without binding DNA directly.
  • Methotrexate treatment lowers NR4A2 and IL-8 levels in arthritis patients' synovial tissue.
  • The findings focus on joint inflammation, not the dopaminergic pathways relevant to NR4A2 syndrome.
low2009-09-01 · Stem cells and development

Human amniotic fluid stem cells do not differentiate into dopamine neurons in vitro or after transplantation in vivo.

Donaldson AE, Cai J, Yang M, Iacovitti L

Human amniotic fluid stem cells cannot become dopamine neurons in the lab or after being transplanted into a Parkinson's disease model, and they do not survive long in the brain due to immune rejection. This means they are not a viable option for cell replacement therapy in Parkinson's disease.

  • hAFS cells do not turn into dopamine neurons in lab tests
  • No dopamine neuron markers appear after differentiation
  • Cells die quickly after transplant due to immune response
  • No long-term survival in brain tissue
  • Not suitable for Parkinson's cell therapy
low2009-08-19 · The Journal of neuroscience : the official journal of the Society for Neuroscience

Subtype specification of GABAergic amacrine cells by the orphan nuclear receptor Nr4a2/Nurr1.

Jiang H, Xiang M

This study identifies a new role for the NR4A2 protein in developing specific types of retinal cells in mice, distinct from its known function in brain dopamine neurons. The findings do not provide direct evidence for treating NR4A2-related syndromes or improving patient outcomes.

  • NR4A2 directs the development of specific GABAergic amacrine cells in mouse retinas.
  • Removing NR4A2 causes loss of certain retinal neurons and an increase in others.
  • This research focuses on eye cell biology, not dopaminergic rescue or human therapy.
low2009-08-12 · PloS one

A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells.

Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L, Freed WJ

A specific combination of four growth factors successfully directs human stem cells to become functional dopamine-producing neurons in a dish. This method removes the need for animal-derived materials, offering a cleaner way to generate these cells for research.

  • Four factors (SDF-1, PTN, IGF2, EFNB1) replace animal cell lines for stem cell differentiation.
  • Generated neurons express key dopamine markers like Nurr1 and Pitx3.
  • Neurons form functional synapses and generate electrical signals in vitro.
  • This is a preclinical protocol for creating dopamine neurons from stem cells.
low2009-08-11 · Molecular cancer research : MCR

NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity.

Zhang T, Wang P, Ren H, Fan J, Wang G

Nurr1 suppresses the tumor suppressor protein p53 to prevent cell death, a mechanism that may contribute to cancer development. This interaction highlights Nurr1's role in regulating cell survival pathways beyond its known function in dopamine neuron maintenance.

  • Nurr1 binds directly to p53 and blocks its ability to activate genes.
  • Reducing Nurr1 levels increases Bax, a protein that triggers cell death.
  • High Nurr1 levels protect cells from chemotherapy-induced apoptosis in this study.
  • The findings suggest Nurr1 may promote cancer by inhibiting p53 activity.
low2009-08-01 · Stem cells (Dayton, Ohio)

Initiation of dopaminergic differentiation of Nurr1(-) mesencephalic precursor cells depends on activation of multiple mitogen-activated protein kinase pathways.

Sabolek M, Baumann B, Heinrich M, Meyer AK, Herborg A, Liebau S, Maisel M, Hermann A, Ventz K, Schwarz J, Wirth T, Storch A

Interleukin-1beta triggers dopaminergic differentiation in rat midbrain precursor cells by activating ERK1/2 and p38 MAP kinase pathways. This process upregulates key transcription factors like Nurr1 and Pitx3, leading to increased tyrosine hydroxylase protein expression. The study demonstrates that these specific signaling cascades are essential for the terminal specification of dopaminergic neurons in this preclinical model.

  • IL-1beta induces dopaminergic differentiation in rat midbrain precursor cells via ERK1/2 and p38 MAP kinases.
  • Inhibition of ERK1/2 or p38 blocks Nurr1 upregulation and dopaminergic specification.
  • The effect is specific to mesencephalic precursors and does not occur in striatal cells.
  • NF-kappaB inhibition actually facilitates, rather than blocks, IL-1beta-induced differentiation.
low2009-08-01 · Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology

[Identification of a possible therapeutic target through pathogenic T cell analysis of multiple sclerosis].

Oki S, Yamamura T

This study identifies NR4A2 as a driver of inflammation in multiple sclerosis by promoting the production of harmful cytokines in T cells. Researchers demonstrate that suppressing NR4A2 reduces these inflammatory signals and prevents disease symptoms in an animal model of MS.

  • NR4A2 is highly active in T cells from multiple sclerosis patients.
  • The protein increases production of inflammatory cytokines IL-17 and IFN-gamma.
  • Silencing NR4A2 reduces cytokine levels in laboratory experiments.
  • Targeting NR4A2 prevents disease transfer in mouse models of MS.
  • NR4A2 is proposed as a potential therapeutic target for autoimmune inflammation.
low2009-07-29 · Annals of the rheumatic diseases

Gene expression profiling reveals a downregulation in immune-associated genes in patients with AS.

Duan R, Leo P, Bradbury L, Brown MA, Thomas G

People with ankylosing spondylitis have lower levels of three immune-related genes—NR4A2, TNFAIP3, and CD69—in their blood cells, suggesting a suppressed immune response. These genes can predict the disease with about 80% accuracy, offering potential for new diagnostic tools.

  • NR4A2 is underactive in ankylosing spondylitis patients
  • Three immune genes are consistently downregulated
  • Gene levels can predict AS with 80% accuracy
  • Findings suggest immune suppression in AS
  • Results may lead to better diagnostics
low2009-06-23 · Experimental neurology

Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis.

Jönsson ME, Ono Y, Björklund A, Thompson LH

This study identifies specific developmental stages of dopamine neuron precursors in mice that are most suitable for transplantation therapies. It finds that early progenitor cells retain the ability to generate functional neurons after grafting, whereas more mature cells do not survive well.

  • Researchers isolated mouse midbrain cells at two embryonic stages for transplantation into rats.
  • Early-stage progenitors successfully generated dopamine neurons in grafts, while later-stage cells did not.
  • Mature dopamine cells expressed tyrosine hydroxylase but survived transplantation poorly.
  • Nigral neuron precursors segregate to lateral areas and can be isolated by Corin expression levels.
low2009-06-17 · Neurology

Layer-specific genes reveal a rudimentary laminar pattern in human nodular heterotopia.

Garbelli R, Rossini L, Moroni RF, Watakabe A, Yamamori T, Tassi L, Bramerio M, Russo GL, Frassoni C, Spreafico R

This study examines the cellular organization of brain malformations in epilepsy patients using gene markers, including Nurr1. It finds that nodular heterotopias retain a rudimentary layer structure and that the overlying cortex shows reduced expression of these specific markers compared to healthy controls.

  • Researchers analyzed brain tissue from 14 epilepsy patients with subcortical nodular heterotopia.
  • Nodules showed rudimentary laminar organization using markers Rorbeta, Er81, and Nurr1.
  • The cortex above the nodules had fewer cells expressing these layer-specific genes.
  • Findings suggest insights into how cortical malformations develop during embryogenesis.
low2009-06-10 · Development (Cambridge, England)

Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons.

Jacobs FM, van der Linden AJ, Wang Y, von Oerthel L, Sul HS, Burbach JP, Smidt MP

This study identifies three new genes regulated by Nurr1 that control the timing and structure of dopamine neuron development in mice. It shows that Nurr1 works with Pitx3 to manage these genes, which are critical for proper neuronal differentiation and axon growth.

  • Nurr1 directly regulates Dlk1, Ptpru, and Klhl1 in developing dopamine neurons.
  • Ptpru and Klhl1 expression depends on both Nurr1 and Pitx3 cooperation.
  • Dlk1 prevents premature dopamine transporter expression during neuronal maturation.
  • Findings clarify molecular pathways driving midbrain dopamine neuron development.
low2009-06-10 · Biochemical and biophysical research communications

Serotonin 5-HT2C receptor-independent expression of hypothalamic NOR1, a novel modulator of food intake and energy balance, in mice.

Nonogaki K, Kaji T, Ohba Y, Sumii M, Wakameda M, Tamari T

This study identifies NOR1, a protein related to the NR4A family, as a regulator of food intake and energy balance in mice. It demonstrates that reduced levels of hypothalamic NOR1 are associated with obesity in specific mouse models, independent of serotonin signaling pathways.

  • NOR1 expression decreases in obese mice with leptin receptor mutations or beta-endorphin deficiency.
  • Injecting NOR1 siRNA suppresses food intake and body weight in mice.
  • Serotonin 5-HT2C receptors do not regulate hypothalamic NOR1 expression.
  • The study focuses on mouse models of obesity, not human genetics or NR4A2-specific mechanisms.
low2009-05-22 · Molecular and cellular endocrinology

Beta-adrenergic signaling regulates NR4A nuclear receptor and metabolic gene expression in multiple tissues.

Myers SA, Eriksson N, Burow R, Wang SC, Muscat GE

Beta-adrenergic stimulation rapidly increases NR4A gene expression and alters metabolic gene activity in mouse heart, liver, and fat tissues. This study maps general signaling pathways in mice but does not address human disease mechanisms or treatments for NR4A2-related syndromes.

  • Beta-adrenergic agonists induce NR4A genes in mouse heart, liver, and adipose tissue within hours.
  • This signaling cross-talk modulates metabolic gene expression across multiple non-neural tissues.
  • The research focuses on general physiology in mice, not neurological development or human patients.
  • No findings relate to dopaminergic neurons, Parkinson's disease, or NR4A2 variant effects.
low2009-05-20 · Brain research bulletin

Generation of dopaminergic neurons from human fetal mesencephalic progenitors after co-culture with striatal-conditioned media and exposure to lowered oxygen.

Liu S, Tian Z, Yin F, Zhao Q, Fan M

This study shows that specific culture conditions improve the generation and maturation of dopaminergic neurons from human fetal tissue in a laboratory dish. The findings do not provide evidence for treating NR4A2-related syndrome in living patients.

  • Dopaminergic neurons mature better when grown with striatal-conditioned media.
  • Lower oxygen levels increase neuronal branching and maturity in cell culture.
  • Combined conditions boost dopamine release from the cultured neurons.
  • The research uses human fetal tissue, not living patients or animal models.
low2009-04-30 · Movement disorders : official journal of the Movement Disorder Society

Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?

Sutherland GT, Halliday GM, Silburn PA, Mastaglia FL, Rowe DB, Boyle RS, O'Sullivan JD, Ly T, Wilton SD, Mellick GD

Common genetic variations in genes linked to familial Parkinson's disease do not strongly increase the risk of sporadic Parkinson's in Australians, with only weak associations found for a few genes. No significant links were found for NR4A2 or other key Parkinson's-related genes.

  • No strong links found between NR4A2 variants and Parkinson's risk
  • Common variants in other Parkinson's genes showed only weak associations
  • Study focused on Australian patients with sporadic Parkinson's
  • Findings suggest minimal contribution from these common variants
  • Results do not support NR4A2 as a major risk factor in this population
low2009-04-30 · FASEB journal : official publication of the Federation of American Societies for Experimental Biology

cAMP opposes the glucose-mediated induction of the L-PK gene by preventing the recruitment of a complex containing ChREBP, HNF4alpha, and CBP.

Burke SJ, Collier JJ, Scott DK

This study shows that cAMP blocks glucose's activation of the L-PK gene by preventing the assembly of a key protein complex involving ChREBP, HNF4alpha, and CBP at the gene's promoter. cAMP redirects CBP to another gene, NR4A2, which may influence cellular metabolism and gene regulation.

  • cAMP stops glucose from turning on the L-PK gene
  • Glucose needs ChREBP, HNF4alpha, and CBP to activate L-PK
  • cAMP disrupts this protein complex at the L-PK promoter
  • CBP is redirected to the NR4A2 gene by cAMP
  • NR4A2 may play a role in metabolic gene regulation
low2009-04-29 · Molecular and cellular endocrinology

Mechanisms of angiotensin II-mediated regulation of aldosterone synthase expression in H295R human adrenocortical and rat adrenal glomerulosa cells.

Szekeres M, Turu G, Orient A, Szalai B, Süpeki K, Cserzo M, Várnai P, Hunyady L

This study examines how angiotensin II regulates the NR4A2 gene in adrenal cells, which is unrelated to the dopaminergic pathways affected in NR4A2 syndrome. The research focuses on steroid hormone production mechanisms in kidney and adrenal tissue rather than brain development or movement disorders. It provides no direct insight into the clinical management or genetic understanding of NR4A2-related syndromes.

  • Study investigates NR4A2 regulation in adrenal cells, not dopaminergic neurons.
  • Focuses on aldosterone synthesis pathways unrelated to NR4A2 syndrome symptoms.
  • No human clinical data or patient phenotypes are presented.
  • Findings do not inform treatment strategies for NR4A2-related conditions.
low2009-04-24 · Neurotoxicity research

Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease.

Federoff HJ

This review proposes that Parkinson's disease may originate from developmental defects in dopamine neuron formation rather than just age-related degeneration. It highlights the transcription factor Nurr1 as a key link between genetic vulnerability and environmental factors in this process.

  • Nurr1 is essential for forming ventral midbrain dopamine neurons during development.
  • The paper suggests Parkinson's disease might be a developmental disorder.
  • Nurr1 regulates VIP, a trophic factor supporting dopamine neurons.
  • A protein called NuIP links upstream signals to Nurr1 activity.
  • No human clinical data or treatment trials are presented.
low2009-04-10 · FEBS letters

Orphan nuclear receptor Nurr1 induces neuron differentiation from embryonic cortical precursor cells via an extrinsic paracrine mechanism.

Bae EJ, Lee HS, Park CH, Lee SH

Overexpressing Nurr1 in rat embryonic brain cells shifts their development toward neurons rather than support cells. This effect occurs through signals released by the modified cells that influence neighboring cells, rather than acting directly inside each cell.

  • Nurr1 overexpression promotes neuron formation at the expense of astrocyte formation in rat cortical cells.
  • The mechanism is extrinsic and paracrine, relying on diffusible factors released by modified cells.
  • The study identifies specific downstream transcription factors responsible for this neurogenic shift.
low2009-04-01 · Annals of the New York Academy of Sciences

Expression of the orphan nuclear receptor NR4A in a putative adenohypophyseal homologue of amphioxus.

Candiani S, Moronti L, Pestarino M

This study identifies a single NR4A gene in the primitive chordate amphioxus and shows it is expressed only in tissue resembling the anterior pituitary gland. The findings describe the evolutionary origins of this transcription factor family rather than providing insights into human disease mechanisms or treatments. This research does not offer actionable information for managing an NR4A2-related syndrome.

  • The study focuses on amphioxus, a primitive invertebrate chordate, not humans.
  • It identifies only one NR4A gene in this species, unlike the three found in humans.
  • Expression is restricted to tissue homologous to the adenohypophysis (anterior pituitary).
  • The work characterizes evolutionary biology rather than clinical neurodevelopmental phenotypes.
  • No connection to dopaminergic neurons or human NR4A2 variants is established.
low2009-03-28 · Journal of neurochemistry

Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.

Gibrat C, Saint-Pierre M, Bousquet M, Lévesque D, Rouillard C, Cicchetti F

This study compares different mouse models of Parkinson's disease to determine which best replicates human pathology. It finds that a specific chronic injection protocol causes dopaminergic neuron loss and alpha-synuclein inclusions, mimicking early-stage Parkinson's more accurately than other methods.

  • The research uses only mouse models, not human patients or clinical data.
  • It investigates MPTP-induced neurodegeneration as a proxy for Parkinson's disease mechanisms.
  • No treatments, gene therapies, or interventions relevant to NR4A2 syndromes are tested.
  • Findings describe animal model characteristics rather than human disease progression or treatment options.